SI1732548T2 - Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem - Google Patents

Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem

Info

Publication number
SI1732548T2
SI1732548T2 SI200531307T SI200531307T SI1732548T2 SI 1732548 T2 SI1732548 T2 SI 1732548T2 SI 200531307 T SI200531307 T SI 200531307T SI 200531307 T SI200531307 T SI 200531307T SI 1732548 T2 SI1732548 T2 SI 1732548T2
Authority
SI
Slovenia
Prior art keywords
methods
sustained release
release aminopyridine
aminopyridine compositions
compositions
Prior art date
Application number
SI200531307T
Other languages
English (en)
Slovenian (sl)
Other versions
SI1732548T1 (sl
Inventor
Andrew R. Blight
Lawrence Marinucci
Ron Cohen
Original Assignee
Acorda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35061389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1732548(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics, Inc. filed Critical Acorda Therapeutics, Inc.
Publication of SI1732548T1 publication Critical patent/SI1732548T1/sl
Publication of SI1732548T2 publication Critical patent/SI1732548T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SI200531307T 2004-04-09 2005-04-11 Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem SI1732548T2 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56089404P 2004-04-09 2004-04-09
US11/102,559 US8354437B2 (en) 2004-04-09 2005-04-08 Method of using sustained release aminopyridine compositions
PCT/US2005/012427 WO2005099701A2 (en) 2004-04-09 2005-04-11 Methods of using sustained release aminopyridine compositions
EP05732613.4A EP1732548B2 (en) 2004-04-09 2005-04-11 Methods of using sustained release aminopyridine compositions

Publications (2)

Publication Number Publication Date
SI1732548T1 SI1732548T1 (sl) 2011-09-30
SI1732548T2 true SI1732548T2 (sl) 2024-02-29

Family

ID=35061389

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200531307T SI1732548T2 (sl) 2004-04-09 2005-04-11 Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem
SI200531728T SI2377536T2 (sl) 2004-04-09 2005-04-11 Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200531728T SI2377536T2 (sl) 2004-04-09 2005-04-11 Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem

Country Status (21)

Country Link
US (13) US8354437B2 (OSRAM)
EP (5) EP1732548B2 (OSRAM)
JP (4) JP5736100B2 (OSRAM)
AT (1) ATE511841T1 (OSRAM)
AU (1) AU2005232732B2 (OSRAM)
CA (2) CA2870734C (OSRAM)
CY (4) CY1111754T1 (OSRAM)
DK (2) DK1732548T4 (OSRAM)
ES (2) ES2367707T5 (OSRAM)
FI (2) FI1732548T4 (OSRAM)
FR (1) FR13C0033I2 (OSRAM)
HR (2) HRP20110497T4 (OSRAM)
HU (1) HUE046320T2 (OSRAM)
LU (2) LU91933I2 (OSRAM)
ME (2) ME01836B (OSRAM)
MX (3) MX370434B (OSRAM)
PL (2) PL2377536T5 (OSRAM)
PT (2) PT2377536E (OSRAM)
RS (2) RS51808B2 (OSRAM)
SI (2) SI1732548T2 (OSRAM)
WO (1) WO2005099701A2 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
AU2013206188B2 (en) * 2005-09-23 2016-04-14 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
CN101827522A (zh) * 2008-09-10 2010-09-08 阿索尔达治疗股份有限公司 持续释放氨基吡啶组合物的使用方法
BRPI1000030A2 (pt) * 2009-02-11 2018-02-14 Acorda Therapeutics Inc métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
EP2995305B1 (en) 2011-01-28 2020-03-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
TWI592156B (zh) 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
EP3381455A1 (en) * 2012-02-13 2018-10-03 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2014093475A1 (en) 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
DK2970101T4 (da) 2013-03-14 2025-11-17 Alkermes Pharma Ireland Ltd Pro-drugs af fumarater og deres anvendelse i behandling af forskellige sygdomme
WO2014151752A1 (en) * 2013-03-15 2014-09-25 University Of Rochester Composition and methods for the treatment of peripheral nerve injury
EP3243516A1 (en) 2013-04-15 2017-11-15 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
UA121323C2 (uk) 2015-02-08 2020-05-12 Алкермес Фарма Айрленд Лімітед Композиції на основі проліків монометилфумарату
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
CA3059180C (en) 2017-04-06 2023-10-17 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1082804A (en) 1912-11-19 1913-12-30 Gerald G Griffin Confetti-machine.
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4386095A (en) 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IE53703B1 (en) 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
IE54286B1 (en) 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
US4851230A (en) 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
IE56459B1 (en) 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4562196A (en) 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4812447A (en) 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4760092A (en) 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
FI895821A7 (fi) 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
TW200462B (OSRAM) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
CA2085785C (en) 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
DE4321030A1 (de) * 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
US6284473B1 (en) 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6288026B1 (en) 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US6600399B1 (en) 2002-02-05 2003-07-29 Roland Pierre Trandafir Transducer motor/generator assembly
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
CA2534711A1 (en) 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP1888056A4 (en) 2005-06-01 2008-09-03 Teva Pharma USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
US20090150180A1 (en) 2005-09-23 2009-06-11 Ron Cohen Method, apparatus and solftware for identifying responders in clinical environment
TWM331106U (en) * 2007-11-12 2008-04-21 Syspotek Corp Solution counter with temperature sensor
CN101827522A (zh) 2008-09-10 2010-09-08 阿索尔达治疗股份有限公司 持续释放氨基吡啶组合物的使用方法
WO2010090730A1 (en) 2009-02-03 2010-08-12 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
BRPI1000030A2 (pt) 2009-02-11 2018-02-14 Acorda Therapeutics Inc métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição.
JO3348B1 (ar) 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
US10255905B2 (en) 2016-06-10 2019-04-09 Google Llc Predicting pronunciations with word stress

Also Published As

Publication number Publication date
AU2005232732B2 (en) 2011-05-12
JP2007532578A (ja) 2007-11-15
US20160199358A1 (en) 2016-07-14
RS51808B2 (sr) 2023-12-29
ES2746354T3 (es) 2020-03-05
US20110166187A1 (en) 2011-07-07
FR13C0033I2 (fr) 2015-11-20
EP2377536A1 (en) 2011-10-19
MXPA06011648A (es) 2008-10-31
DK2377536T4 (da) 2022-11-07
AU2005232732A1 (en) 2005-10-27
US20180200241A1 (en) 2018-07-19
LU92275I9 (OSRAM) 2019-01-03
US20170209422A1 (en) 2017-07-27
PT2377536E (pt) 2013-04-11
HRP20130424T4 (hr) 2022-10-28
EP2377536B1 (en) 2013-03-06
EP2460521B1 (en) 2019-06-12
ME01836B (me) 2014-12-20
US9925173B2 (en) 2018-03-27
US20120164078A1 (en) 2012-06-28
EP1732548B2 (en) 2023-08-30
HRP20130424T1 (en) 2013-06-30
PL1732548T5 (pl) 2024-11-04
ES2367707T3 (es) 2011-11-07
EP1732548A4 (en) 2009-06-03
US20150080436A1 (en) 2015-03-19
CY2013035I1 (el) 2020-05-29
HK1162971A1 (en) 2012-09-07
SI2377536T1 (sl) 2013-07-31
LU91933I2 (fr) 2013-01-18
PL2377536T3 (pl) 2013-08-30
US20120064007A1 (en) 2012-03-15
CA2562277A1 (en) 2005-10-27
CA2870734C (en) 2022-08-16
US20050228030A1 (en) 2005-10-13
MX370434B (es) 2019-12-13
WO2005099701A3 (en) 2006-03-23
RS51808B8 (sr) 2019-08-30
RS51808B (sr) 2011-12-31
EP3922248A1 (en) 2021-12-15
US20170071924A1 (en) 2017-03-16
PT1732548E (pt) 2011-09-16
FI1732548T4 (fi) 2023-11-30
FR13C0033I1 (fr) 2013-08-09
US20170273960A1 (en) 2017-09-28
WO2005099701A2 (en) 2005-10-27
SI1732548T1 (sl) 2011-09-30
PL1732548T4 (pl) 2012-03-30
CA2870734A1 (en) 2005-10-27
US20140039015A1 (en) 2014-02-06
PL2377536T5 (pl) 2023-03-06
EP1732548B9 (en) 2012-03-21
CY2024026I2 (el) 2025-03-28
MX2019015036A (es) 2020-02-24
HRP20110497T4 (hr) 2024-03-29
LU92275I2 (fr) 2015-09-03
SI2377536T2 (sl) 2022-11-30
US20110166188A1 (en) 2011-07-07
EP1732548A2 (en) 2006-12-20
FIC20130042I1 (fi) 2013-08-13
HRP20110497T1 (hr) 2011-08-31
JP5736100B2 (ja) 2015-06-17
JP5914626B2 (ja) 2016-05-11
JP2012188427A (ja) 2012-10-04
US8440703B2 (en) 2013-05-14
PL1732548T3 (pl) 2011-11-30
CA2562277C (en) 2015-01-27
EP2377536B2 (en) 2022-08-17
JP2015057451A (ja) 2015-03-26
CY1114073T1 (el) 2016-07-27
DK1732548T4 (da) 2023-11-20
RS53371B2 (sr) 2022-11-30
HUE046320T2 (hu) 2020-02-28
ATE511841T1 (de) 2011-06-15
US8354437B2 (en) 2013-01-15
EP1732548B1 (en) 2011-06-08
CY2012004I2 (el) 2015-10-07
JP2015157861A (ja) 2015-09-03
ES2367707T9 (es) 2012-07-05
ME01721B (me) 2014-09-20
RS53371B (sr) 2014-10-31
US20110166189A1 (en) 2011-07-07
EP2460521A1 (en) 2012-06-06
DK1732548T3 (da) 2011-09-26
DK2377536T3 (da) 2013-03-25
RS51808B9 (sr) 2019-06-28
EP2422782A1 (en) 2012-02-29
CY1111754T1 (el) 2015-10-07
CY2012004I1 (el) 2015-10-07
ES2367707T5 (es) 2024-04-25

Similar Documents

Publication Publication Date Title
CY2013035I1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
GB0406819D0 (en) Controlled release compositions
IL216401A0 (en) Sustained release of antinfectives
ZA200707440B (en) Compositions and methods of making sustained release liquid formulations
IL184460A0 (en) Sustained release pharmaeutical formulations
PT1931315E (pt) Formulações de libertação sustentada de nalbufina
IL182639A0 (en) Immunogenic composition
IL192098A (en) Preparations and Methods for Manufacturing Preparations
IL185800A0 (en) Controlled release formulations of octreotide
IL178596A0 (en) Sustained release formulations
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
ZA200610204B (en) Irinotecan preparation
EP1797926A4 (en) FORMULATION OF A SURFACTANT
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
GB0409066D0 (en) Surfactant composition
IL178383A0 (en) Delayed release formulations of 6-mercaptopurine
IL177328A0 (en) Controlled release formulations
IL180195A0 (en) Aequorin-containing compositions and methods of using same
GB0412584D0 (en) Composition of matter
GB0421079D0 (en) Immunogenic composition
PL1868450T3 (pl) Kompozycje o przedłużonym uwalnianiu energii
ZA200606977B (en) Alkaloid formulations
HK1159948A (en) Methods of using sustained release aminopyridine compositions
AU2004903283A0 (en) Sustained release vaccine composition
ZA200702752B (en) Immunogenic compositions